We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Screening Test Detects Chlamydial Infection

By LabMedica International staff writers
Posted on 26 Mar 2013
A rapid nonculture method for detection of Chlamydia trachomatis has been developed based on the measurement of specific enzymatic activity in urogenital tract specimens.

The method is based on the level of the activity of α-mannosidase, a gylcoside hydrolase involved in the maturation and degradation of glycoprotein-linked oligosaccharides, on its specific chromogen. More...


Scientists at Zhengzhou University (China) evaluated the performance of a method, which measured the α-mannosidase activities of C. trachomatis serotype D strain and 29 standard strains related to clinical urogenital pathogens. They also assayed 553 urogenital tract specimens via cell culture method and ligase chain reaction method (LCR), adopting an expanded gold standard.

For the 203 male cases, three urethral discharge specimens from 151 outpatients or three prostate massage liquid specimens from 52 outpatients were collected with sterile rayon swabs. For the 350 female cases, three cervical secretion specimens were collected from 232 outpatients, or three vaginal secretion specimens were collected from 118 outpatients, with sterile rayon swabs using vaginal forceps.

The enzymatic method was based on the substrate 6-chloro-3-indolyl-α-D-mannoside and the chromogenic reagent contained fast violet B salt (J&K Chemical; Shanghai, China; www.jkchemical.com). The result was considered to be positive when the optical density (OD) at 512 nm was greater than 0.150, if the color changed from colorless to red or brown after 15 minutes of incubation at 37 °C. Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method.

Of the 553 clinical samples, 132 samples were positive with the OD ranging from 0.161 to 1.955, and 421 samples were negative with OD ranging from 0.013 to 0.142. The sensitivity of the enzymatic method was 91.5%, and the specificity of this method was 90.0%.

The authors concluded that they had demonstrated that there were no significant differences between the enzymatic method and the reference method if prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for C. trachomatis in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and specialized equipment is not essential. The study was published on January 24, 2013, in, the BioMed Central journal BMC Infectious Diseases.

Related Links:

Zhengzhou University
J&K Chemical



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.